Related Experiment Video

Updated: May 12, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070

G O'Boyle1, I Swidenbank, H Marshall

  • 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

British Journal of Cancer
|March 30, 2013
PubMed
Abstract

Insights

A new drug, AMD11070, effectively blocks CXCR4 to stop melanoma metastasis to the liver. This oral therapy shows promise for both B-RAF mutated and wild-type melanomas.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Metastatic melanoma remains incurable despite advanced therapies.
  • The chemokine receptor CXCR4 plays a key role in melanoma metastasis to organs like the liver.
  • Current therapeutic strategies targeting CXCR4 have faced challenges.

Purpose of the Study:

  • To evaluate AMD11070, an orally bioavailable CXCR4 inhibitor, for its efficacy in blocking melanoma cell migration.
  • To compare AMD11070's effectiveness against AMD3100, a known CXCR4 antagonist.

Main Methods:

  • In vitro testing of AMD11070 on melanoma cell migration.
  • Comparative analysis with AMD3100.
  • Assessment of AMD11070 sensitivity in relation to B-RAF-V600E expression.

Main Results:

  • AMD11070 significantly inhibited melanoma cell migration.
  • AMD11070 demonstrated superior efficacy compared to AMD3100.
  • Melanoma cell sensitivity to AMD11070 was not influenced by B-RAF-V600E expression.

Conclusions:

  • Liver myofibroblasts secrete CXCL12, driving CXCR4-expressing melanoma cell migration into the liver.
  • AMD11070 blockade of the CXCL12/CXCR4 axis offers a novel therapeutic approach.
  • This strategy is potentially effective for both B-RAF wild-type and mutated melanomas.

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Concept Videos

Chemotaxis and Direction of Cell Migration01:21

Chemotaxis and Direction of Cell Migration

Cells can detect chemical cues in their environment and reorganize the cytoskeleton to migrate toward them or away from them. This directional migration, called chemotaxis, is essential during embryogenesis and development, immune response, tissue repair and regeneration, and reproduction. These chemical cues can either attract or repel the cell's movement. For example, axon development is determined by a combination of chemoattractants and chemorepellents that direct the growing axon towards...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...